Mitochondrial Peptide Comparison
Overview
A side-by-side comparison of the four mitochondrial and metabolic peptides in this database — MOTS-c, SS-31 (Elamipretide), Humanin and AOD-9604 — across chemistry, mechanism, pharmacology, safety and research positioning. They target very different points of metabolism, so the comparison is mainly about matching a peptide to a research question.
Overview
| Feature | MOTS-c | SS-31 | Humanin | AOD-9604 |
|---|---|---|---|---|
| Class | Mito-derived peptide | Cardiolipin-targeting tetrapeptide | Mito-derived peptide | Modified hGH fragment |
| Sequence length | 16 aa | 4 aa | 24 aa | 16 aa |
| Primary mechanism | AMPK / exercise mimetic | Cardiolipin / ETC stabilization | Bax/Bid anti-apoptotic | Lipolysis (HSL) |
| Main research area | Insulin sensitivity, metabolism | Mitochondrial function, ischemia | Neuroprotection, longevity | Fat metabolism, cartilage |
Chemical Comparison
Sequences and weights below are the published/corrected values.
| Property | MOTS-c | SS-31 | Humanin | AOD-9604 |
|---|---|---|---|---|
| CAS number | 1626405-30-4 | 736992-21-5 | 330936-65-3 | 221231-10-3 |
| Molecular weight | ≈ 2174.6 | 639.81 | ≈ 2687.2 | ≈ 1815.1 |
| Sequence | MRWQEMGYIFYPRKLR | D-Arg-Dmt-Lys-Phe-NH₂ | MAPRGFSCLLLLTSEIDLPVKRRA | YLRIVQCRSVEGSCGF |
| Special features | Arg-rich | D-Arg + Dmt | Met + Cys | Disulfide bond |
| Purity (HPLC) | ≥ 98% | ≥ 98% | ≥ 98% | ≥ 98% |
Mechanism Comparison
| Pathway | MOTS-c | SS-31 | Humanin | AOD-9604 |
|---|---|---|---|---|
| Primary target | AMPK / folate | Cardiolipin (IMM) | Bax, Bid, IGFBP3 | Adipocyte HSL |
| Mitochondrial action | UPRmt / biogenesis | ETC supercomplexes | MOMP inhibition | Not direct |
| Insulin sensitivity | Strong | Indirect | Moderate | — |
| Lipolysis | FGF21-mediated | — | — | Direct |
| Neuroprotection | Moderate | Moderate | Strong | — |
| Exercise mimetic | Yes | — | — | — |
Pharmacological Comparison
| Parameter | MOTS-c | SS-31 | Humanin | AOD-9604 |
|---|---|---|---|---|
| Half-life | ≈ 2–4 h | ≈ 2–4 h | ≈ 1–3 h | ≈ 2–4 h |
| Bioavailability (SC) | ≈ 50–70% | ≈ 60–80% | ≈ 40–60% | ≈ 60–80% |
| Protein binding | Moderate | ≈ 90% | Moderate | Moderate |
| Routes | SC, IP | SC, IV | SC, IV, IP | SC |
Research Evidence Comparison
A qualitative view of research focus and stage (research context; specific numerical outcomes are not restated as claims):
| Research area | MOTS-c | SS-31 | Humanin | AOD-9604 |
|---|---|---|---|---|
| Metabolic / insulin | Strong | Indirect | Moderate | Fat-specific |
| Mitochondrial function | Moderate | Strong | Moderate | — |
| Neuroprotection / longevity | Emerging | Emerging | Strong | — |
| Clinical stage | Pilot / preclinical | Phase 2–3 | Preclinical / pilot | Early clinical |
Safety Profile Comparison
Published research observations; all four are for research use only, not for human or veterinary use.
| Category | MOTS-c | SS-31 | Humanin | AOD-9604 |
|---|---|---|---|---|
| Injection reactions | Mild | Mild | Mild | Mild |
| GI tolerability | Well tolerated | Mild nausea | Well tolerated | Well tolerated |
| Cytotoxicity | None observed | None observed | None observed | None observed |
| Research status | Preclinical | Clinical-stage | Preclinical | Early clinical |
Research Dosing Comparison
Reconstitution-oriented reference ranges from the literature; not human dosing guidance.
| Parameter | MOTS-c | SS-31 | Humanin | AOD-9604 |
|---|---|---|---|---|
| Typical research dose | 5–15 mg | 0.5–2 mg | 2–8 mg | 300–1000 µg |
| Frequency | 1–2× / week | Daily | 1–2× / day | Daily |
| Route | SC / IP | SC / IV | SC / IV | SC |
Selection Considerations
Choose MOTS-c when
The focus is insulin sensitivity, AMPK/exercise-mimetic metabolism or whole-body metabolic regulation.
Choose SS-31 when
The focus is mitochondrial bioenergetics itself — cardiolipin, electron transport, ischemia–reperfusion.
Choose Humanin when
The focus is cytoprotection, neuroprotection or longevity via anti-apoptotic signalling.
Choose AOD-9604 when
The focus is adipose-tissue lipolysis or cartilage research, without GH/IGF-1 axis effects.
Analytical Method Comparison
| Parameter | MOTS-c | SS-31 | Humanin | AOD-9604 |
|---|---|---|---|---|
| HPLC column | C18 | C18 | C18 | C18 |
| Detection | UV 214 nm | UV 214 nm | UV 214 nm | UV 214 nm |
| MS ionization | ESI+ | ESI+ | ESI+ | ESI+ |
| Special QC | Arg-rich sequence | D-Arg / Dmt confirmation | Met/Cys oxidation control | Disulfide confirmation |
Selected References
- Lee C, et al. MOTS-c promotes metabolic homeostasis. Cell Metabolism, 2015.
- Szeto HH. Cardiolipin-targeting peptides (SS-31 / elamipretide) research literature.
- Hashimoto Y, et al. Humanin, a neuroprotective factor. Proceedings of the National Academy of Sciences, 2001.
- Ng FM, et al. Lipolytic hGH fragment AOD-9604 metabolic studies.
Quality & Supply
- All four peptides available research-grade, HPLC-characterized with a Certificate of Analysis per batch
- Identity confirmed by LC-MS
- Research samples through to bulk, with worldwide delivery
- Custom quantities and packaging on request
Need Mitochondrial Peptide Comparison — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
